Skip to content
DataLookout
Menu

NCT05442190

Topical SGX302 for Mild-to-Moderate Psoriasis

StatusCompleted
PhasePhase 2
SponsorSoligenix
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026
    • Eligibility criteria expanded, about 7 words
    • Primary endpoint revised
    • Secondary endpoints: 3 to 2
  2. Minor Interventions: Hypericin (Drug), Placebo (Drug) to Hypericin (Drug)v7
  3. Minor Trial status: Recruiting to Completedv6 Show 4 more changesShow less
    • Enrollment target: estimated 47 to confirmed 15
    • Primary completion date changed from estimate of Oct 2025 to Oct 22, 2025
    • Study completion date changed from estimate of Dec 2025 to Nov 17, 2025
    • Site details revised
  4. Minor Primary completion date: Apr 2025 to Oct 2025
    • Study completion date: Jun 2025 to Dec 2025
    v5
  5. Minor Enrollment target: 42 to 47
    • Study arms: 2 to 3
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Primary completion date: Oct 2023 to Apr 2025
    • Study completion date: Dec 2023 to Jun 2025
    v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Enrollment target: 32 to 42
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2022 to Dec 14, 2022
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
Timeframe: 18 weeks

Secondary (2)

SkinDex-29 Score
Dermatology Life Quality Index Score

Arms and interventions

Cohort 1 - SGX302 Ointment (0.25 % Hypericin)Experimental

SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a gradual escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Experimental

SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

Cohort 3 - SGX302 Gel (0.25 % Hypericin)Experimental

SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 40 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

Drugs: Hypericin

Sites

1 site in 1 country

  • Therapeutics Clinical ResearchSan Diego, California, United States